Paion AG
XETRA:PA8
Intrinsic Value
PAION AG operates as a pharmaceutical company. [ Read More ]
The intrinsic value of one
PA8
stock under the Base Case scenario is
16.51
EUR.
Compared to the current market price of 0.25 EUR,
Paion AG
is
Undervalued by 98%.
PA8's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PA8 or that its price is influenced by factors unrelated to fundamentals.
Paion AG's market capitalization is 1.8m EUR.
PA8 stock price is 0.25 EUR.
PA8 stock price (0.25 EUR) is 98% less than its Intrinsic Value (16.51 EUR).
PA8. Open DCF Valuation
PA8.
PA8's long-term liabilties (35m EUR) exceed its long-term assets (32m EUR).
PA8 has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
PA8's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 22%.
PA8's short-term liabilties (17m EUR) exceed its short-term assets (13m EUR).
PA8's ROE (Return on Equity) for the past 12 months is negative and is equal to -9%.
PA8's Revenue has grown by an exceptional 366% over the past 12 months.
PA8 has positive Operating Income for the last twelve months.
PA8 has negative Net Income for the last twelve months.
PA8 has negative three-year average ROE (Return on Equity): -3%. The company is not efficient at transforming stockholders' equity into net income.
PA8 has positive Gross Profit for the last twelve months.
PA8 has positive Net Debt. This means that the company has more debt (18m EUR) than cash and short-term investments (5m EUR).
PA8's D/E (Debt to Equity) is very high and is equal to 2.86.
PA8 has positive Free Cash Flow for the last twelve months.
PA8's Altman Z-Score is very low and is equal to -6.21.
PA8 generates enough operating income (2m EUR) to cover interest payments on its debt (1m EUR).
Fundamental Analysis
Paion AG
Balance Sheet Decomposition
Paion AG
| Current Assets | 17.8m |
| Cash & Short-Term Investments | 10.6m |
| Receivables | 2.2m |
| Other Current Assets | 5m |
| Non-Current Assets | 20.3m |
| PP&E | 759k |
| Intangibles | 19.6m |
| Current Liabilities | 12.6m |
| Accounts Payable | 8m |
| Other Current Liabilities | 4.6m |
| Non-Current Liabilities | 18.9m |
| Long-Term Debt | 18.9m |
| Other Non-Current Liabilities | 26k |
Earnings Waterfall
Paion AG
|
Revenue
|
33.2m
EUR
|
|
Cost of Revenue
|
-2m
EUR
|
|
Gross Profit
|
31.3m
EUR
|
|
Operating Expenses
|
-29.8m
EUR
|
|
Operating Income
|
1.5m
EUR
|
|
Other Expenses
|
-2.1m
EUR
|
|
Net Income
|
-579k
EUR
|
Free Cash Flow Analysis
Paion AG
PA8 Profitability Score
Profitability Due Diligence
Paion AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Paion AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
PA8 Solvency Score
Solvency Due Diligence
Paion AG's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Score
Paion AG's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PA8 Price Targets Summary
Paion AG
Shareholder Return
PA8 Price
Paion AG
| Average Annual Return | -12.7% |
| Standard Deviation of Annual Returns | 30.7% |
| Max Drawdown | -99% |
| Market Capitalization | 1.8m EUR |
| Shares Outstanding | 7 092 063 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Paion AG
Country
Industry
Market Cap
Dividend Yield
Description
PAION AG operates as a pharmaceutical company. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 56 full-time employees. The company went IPO on 2012-03-29. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
You don't have any saved screeners yet
